STI571: A gene product-targeted therapy for leukemia
作者： Michael J. Mauro , Brian J. Druker
DOI: 10.1007/S11912-001-0054-Z
关键词:
摘要: Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of constitutively activated bcr-abl tyrosine kinase. Characterized clinically marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens transplantation, with transplantation being only curative therapy. Through rational drug development, STI571, kinase inhibitor, has emerged as paradigm for gene product-targeted therapy, offering new hope expanded treatment patients CML.
springer.com
elsevier.com
sci-hub.se 参考文章(38)
Donald B. Kohn, Gerhard Bauer, C. Robert Rice, J.C. Rothschild, Denise A. Carbonaro, Penelope Valdez, Qian-lin Hao, Chen Zhou, Ingrid Bahner, Karen Kearns, Kate Brody, Sarah Fox, Elizabeth Haden, Kathy Wilson, Cathy Salata, Cathy Dolan, Charles Wetter, Estuardo Aguilar-Cordova, Joseph Church, A Clinical Trial of Retroviral-Mediated Transfer of arev-Responsive Element Decoy Gene Into CD34+Cells From the Bone Marrow of Human Immunodeficiency Virus-1–Infected Children Blood. ,vol. 94, pp. 368- 371 ,(1999) , 10.1182/BLOOD.V94.1.368.413A47_368_371
Martin Carroll, Sayuri Ohno-Jones, Shu Tamura, Elisabeth Buchdunger, Jürg Zimmermann, Nicholas B. Lydon, D. Gary Gilliland, Brian J. Druker, CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins Blood. ,vol. 90, pp. 4947- 4952 ,(1997) , 10.1182/BLOOD.V90.12.4947.4947_4947_4952
Philipp le Coutre, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino, Carlo Gambacorti-Passerini, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. ,vol. 95, pp. 1758- 1766 ,(2000) , 10.1182/BLOOD.V95.5.1758.005A41_1758_1766
Michael W.N. Deininger, John M. Goldman, Nicholas Lydon, Junia V. Melo, The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells Blood. ,vol. 90, pp. 3691- 3698 ,(1997) , 10.1182/BLOOD.V90.9.3691
François Xavier Mahon, Michael W. N. Deininger, Beate Schultheis, Jérome Chabrol, Josy Reiffers, John M. Goldman, Junia V. Melo, Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood. ,vol. 96, pp. 1070- 1079 ,(2000) , 10.1182/BLOOD.V96.3.1070
P. C. Nowell, A minute chromosome in human chronic granulocytic leukemia Science. ,vol. 132, pp. 1497- ,(1960)
Guofu Fang, Caryn Naekyung Kim, Charles L. Perkins, Nimmanapalli Ramadevi, Elliott Winton, Sylvie Wittmann, Kapil N. Bhalla, CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs Blood. ,vol. 96, pp. 2246- 2253 ,(2000) , 10.1182/BLOOD.V96.6.2246
Gurmeet Kaur, Aviv Gazit, Alexander Levitzki, Emily Stowe, David A Cooney, Edward A Sausville, Tyrphostin induced growth inhibition : correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia Anti-Cancer Drugs. ,vol. 5, pp. 213- 222 ,(1994) , 10.1097/00001813-199404000-00013
Nora Heisterkamp, Guido Jenster, Joanne ten Hoeve, Daniel Zovich, Paul K. Pattengale, John Groffen, Acute leukaemia in bcr/abl transgenic mice Nature. ,vol. 344, pp. 251- 253 ,(1990) , 10.1038/344251A0
Bernd Kasper, Stefan Fruehauf, Bernd Schiedlmeier, Elisabeth Buchdunger, Anthony D. Ho, W. Jens Zeller, Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemotherapy and Pharmacology. ,vol. 44, pp. 433- 438 ,(1999) , 10.1007/S002800051001